As of close of business last night, Pyxis Oncology Inc’s stock clocked out at $4.78, down -1.65% from its previous closing price of $4.86. In other words, the price has decreased by -$0.0800 from its previous closing price. On the day, 629841 shares were traded.
Ratios:
To gain a deeper understanding of PYXS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.91 and its Current Ratio is at 4.91. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.15.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on February 09, 2024, initiated with a Buy rating and assigned the stock a target price of $8.
On January 23, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $12.
On September 05, 2023, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $7.RBC Capital Mkts initiated its Outperform rating on September 05, 2023, with a $7 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 28 when Connealy Pamela Ann bought 8,000 shares for $1.87 per share. The transaction valued at 14,960 led to the insider holds 818,532 shares of the business.
Connealy Pamela Ann bought 6,426 shares of PYXS for $11,868 on Sep 27. The CFO and COO now owns 810,532 shares after completing the transaction at $1.85 per share. On Sep 27, another insider, Wadhane Jitendra, who serves as the Chief Accounting Officer of the company, bought 2,500 shares for $1.87 each. As a result, the insider paid 4,675 and bolstered with 226,937 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PYXS now has a Market Capitalization of 211.86M and an Enterprise Value of -110.18M.
Stock Price History:
Over the past 52 weeks, PYXS has reached a high of $6.92, while it has fallen to a 52-week low of $1.35. The 50-Day Moving Average of the stock is 3.0128, while the 200-Day Moving Average is calculated to be 2.4841.
Shares Statistics:
It appears that PYXS traded 519.99K shares on average per day over the past three months and 783.34k shares per day over the past ten days. A total of 34.96M shares are outstanding, with a floating share count of 30.41M. Insiders hold about 31.35% of the company’s shares, while institutions hold 28.67% stake in the company. Shares short for PYXS as of Jan 31, 2024 were 784.62k with a Short Ratio of 1.51, compared to 633.99k on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 1.77% and a Short% of Float of 2.13%.
Earnings Estimates
As of right now, 6 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.47 for the current quarter, with a high estimate of -$0.35 and a low estimate of -$0.57, while EPS last year was -$1.01. The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.24 and low estimates of -$0.55.
Analysts are recommending an EPS of between -$1.67 and -$2.09 for the fiscal current year, implying an average EPS of -$1.95. EPS for the following year is -$1.38, with 6 analysts recommending between -$0.93 and -$2.1.
